+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: results of a randomized double-blind, placebo-controlled clinical trial



Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: results of a randomized double-blind, placebo-controlled clinical trial



International Immunopharmacology 17(3): 917-923



This study was designed to assess the effect of sertraline on serum concentrations of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), IL-10 and high-sensitivity C-reactive protein (hs-CRP) of depressed hemodialysis (HD) patients. During a randomized, double-blind, placebo-controlled trial, fifty depressed HD patients were allocated to receive sertraline or placebo for 12 weeks. Patients' depression was assessed using Beck Depression Inventory-second edition (BDI-II). Biochemical parameters (hemoglobin, serum albumin, iron stores, etc.) and serum IL-6, IL-10, TNF-α, and hs-CRP levels were measured at baseline and at weeks 6 and 12 of the study. Sertraline significantly improved depression symptoms in 47.5% of the patients. Compared with placebo, serum levels of IL-6 significantly decreased (P<0.01) in the sertraline group at week 12 of the study. Although serum level of TNF-α decreased and serum level of IL-10 increased in sertraline group at week 12 versus initiation of the study, no significant differences were found between sertraline and placebo groups. Serum hs-CRP did not display differences neither for inter- nor intra-group comparisons. Hemoglobin and serum albumin concentrations were significantly lower at week 12 in the placebo versus sertraline group (P=0.012 and P=0.006, respectively). No significant differences were observed in the inflammatory mediators between responders and non-responders to sertraline. Compared with placebo, sertraline significantly decreased serum level of IL-6. The anti-inflammatory effect of sertraline was independent to its efficacy for depression treatment. Sertraline could be a promising strategy to reduce the systemic inflammation and to treat depression in HD patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055727861

Download citation: RISBibTeXText

PMID: 24121064

DOI: 10.1016/j.intimp.2013.09.020


Related references

Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. Nephrology Dialysis Transplantation 27(5): 2023-2028, 2012

Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. American Heart Journal 156(3): 437-444, 2008

Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. American Journal of Psychiatry 157(10): 1686-1689, 2000

A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression. Psychopharmacology 231(5): 939-948, 2014

Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Archives of General Psychiatry 63(5): 521-529, 2006

Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Archives of General Psychiatry 64(6): 679-688, 2007

Short-term effect of high-dose vitamin D on the level of interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation 22(6): 400-404, 2015

A randomized double-blind placebo controlled trial of the selective serotonin reuptake inhibitor sertraline for major depression after acute coronary syndromes The SADHART trial. Circulation 104(17 Suppl.): II 344, 2001

The Beyond Ageing Project Phase 2--a double-blind, selective prevention, randomised, placebo-controlled trial of omega-3 fatty acids and sertraline in an older age cohort at risk for depression: study protocol for a randomized controlled trial. Trials 16: 247, 2015

Vitamin D Decreases Beck Depression Inventory Score in Patients with Mild to Moderate Ulcerative Colitis: A Double-Blind Randomized Placebo-Controlled Trial. Journal of Dietary Supplements 16(5): 541-549, 2019

Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. American Journal of Nephrology 36(5): 478-487, 2012

Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. Journal of Clinical Psychiatry 61(11): 821-827, 2000

Influence of cholecalciferol supplementation in hemodialysis patients on monocyte subsets: a randomized, double-blind, placebo-controlled clinical trial. Nephron. Clinical Practice 123(3-4): 209-219, 2013

Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial. Bmc Nephrology 15: 98, 2014

High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. Journal of Infectious Diseases 203(6): 756-764, 2011